Drugs that contain Palbociclib

1. List of Ibrance drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6936612 PFIZER 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
Jan, 2023

(14 days ago)

US7208489 PFIZER 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones
Jan, 2023

(14 days ago)

USRE47739 PFIZER 2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones
Mar, 2027

(4 years from now)

US10723730 PFIZER Solid forms of a selective CDK4/6 inhibitor
Feb, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7456168 PFIZER 2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones
Jan, 2023

(14 days ago)

US11065250 PFIZER Solid dosage forms of palbociclib
May, 2036

(13 years from now)

Market Authorisation Date: 03 February, 2015

Treatment: Palbociclib for hr-pos. her2-neg. advanced or metastatic breast cancer in combo with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or men, or with fulvestrant in pts with disease progression after endocrine therapy


How can I launch a generic of IBRANCE before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic